ZA201201822B - Use of guaifenesin for inhibiting mucin secretion - Google Patents

Use of guaifenesin for inhibiting mucin secretion

Info

Publication number
ZA201201822B
ZA201201822B ZA2012/01822A ZA201201822A ZA201201822B ZA 201201822 B ZA201201822 B ZA 201201822B ZA 2012/01822 A ZA2012/01822 A ZA 2012/01822A ZA 201201822 A ZA201201822 A ZA 201201822A ZA 201201822 B ZA201201822 B ZA 201201822B
Authority
ZA
South Africa
Prior art keywords
guaifenesin
mucin secretion
inhibiting mucin
inhibiting
secretion
Prior art date
Application number
ZA2012/01822A
Inventor
Helmut Albrecht
K Chul Kim
Jeanclare Seagrave
Bruce K Rubin
Gail Solomon
Original Assignee
Reckitt Benckiser Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/558,517 external-priority patent/US20110065744A1/en
Priority claimed from GBGB1002039.4A external-priority patent/GB201002039D0/en
Application filed by Reckitt Benckiser Llc filed Critical Reckitt Benckiser Llc
Publication of ZA201201822B publication Critical patent/ZA201201822B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2012/01822A 2009-09-12 2012-03-13 Use of guaifenesin for inhibiting mucin secretion ZA201201822B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/558,517 US20110065744A1 (en) 2009-09-12 2009-09-12 Method Of Inhibiting Mucin Secretion
GBGB1002039.4A GB201002039D0 (en) 2010-02-09 2010-02-09 Method of inhibiting mucin secretion
PCT/GB2010/051525 WO2011030163A1 (en) 2009-09-12 2010-09-13 Use of guaifenesin for inhibiting mucin secretion

Publications (1)

Publication Number Publication Date
ZA201201822B true ZA201201822B (en) 2013-05-29

Family

ID=42941393

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/01822A ZA201201822B (en) 2009-09-12 2012-03-13 Use of guaifenesin for inhibiting mucin secretion

Country Status (12)

Country Link
EP (1) EP2475360A1 (en)
JP (1) JP2013504554A (en)
KR (1) KR20120068889A (en)
CN (1) CN102596189A (en)
AU (1) AU2010294008B2 (en)
BR (1) BR112012005517A2 (en)
CA (1) CA2773611A1 (en)
MX (1) MX2012003042A (en)
MY (1) MY161187A (en)
RU (1) RU2012114323A (en)
WO (1) WO2011030163A1 (en)
ZA (1) ZA201201822B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6525203B2 (en) * 2012-04-06 2019-06-05 ザ ユーエイビー リサーチ ファウンデーションＴｈｅ ＵＡＢ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ Methods for increasing CFTR activity
KR102211605B1 (en) * 2018-02-26 2021-02-04 대한민국 Methods for Screening Therapeutic Agents for Airway Conduct MucinSecretion Inhibitor Using the Frog Embryo

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA963590B (en) * 1995-05-10 1996-11-19 Adcock Ingram Ltd Pharmaceutical composition
US6846799B1 (en) * 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US20040029864A1 (en) * 2002-02-04 2004-02-12 Pharmacia Corporation Treatment of colds and cough with a combination of a cyclooxygenase-2 selective inhibitor and a colds and cough active ingredient and compositions thereof
AU2004249775A1 (en) * 2003-06-19 2004-12-29 Genaera Corporation Mucin synthesis inhibitors
US20050095288A1 (en) * 2003-11-03 2005-05-05 Andrx Labs, Llc Decongestant and expectorant tablets
US20050266032A1 (en) * 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US20080014261A1 (en) * 2006-07-12 2008-01-17 Giordano John A Non-narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
US20090202633A1 (en) * 2008-01-03 2009-08-13 Siva Ramakrishna Velaga Extended release formulations of guaifenesin

Also Published As

Publication number Publication date
RU2012114323A (en) 2013-10-20
EP2475360A1 (en) 2012-07-18
CA2773611A1 (en) 2011-03-17
BR112012005517A2 (en) 2016-04-19
KR20120068889A (en) 2012-06-27
MX2012003042A (en) 2012-05-29
AU2010294008B2 (en) 2014-08-14
AU2010294008A1 (en) 2012-04-05
WO2011030163A1 (en) 2011-03-17
CN102596189A (en) 2012-07-18
JP2013504554A (en) 2013-02-07
MY161187A (en) 2017-04-14

Similar Documents

Publication Publication Date Title
HK1254977A1 (en) Crystalline form of sofosbuvir
ZA201203289B (en) Use of bethanechol for treatment of zerostomia
EP2440054A4 (en) Pyridil-triazine inhibitors of hedgehog signaling
EP2515713A4 (en) Stabilisation of objects
IL218018A0 (en) Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions
EP2438246A4 (en) Aspects of construction
ZA201206456B (en) Uses of dgati inhibitors
IL215865B (en) Formulation of meloxicam
GB0919097D0 (en) Treatment of hard surfaces
HK1166280A1 (en) Composition for treatment of tuberculosis
IL216612A0 (en) Inhhibition of inflammation using antagonists of muc1
HK1171624A1 (en) Inhibitors of cognitive decline
HK1167323A1 (en) Inhibitors of cognitive decline
PL2624836T3 (en) Bepotastine compositions
SI2506840T1 (en) Uses of hypoxia-inducible factor inhibitors
EP2515709A4 (en) Stabilisation of objects
EP2421882A4 (en) Angiogenesis inhibitors
EP2496230A4 (en) Ire-1 alpha inhibitors
IL217756A0 (en) Inhibitors of jnk
ZA201201822B (en) Use of guaifenesin for inhibiting mucin secretion
PT2411376E (en) Inhibitors of nf-kb
IL215486A0 (en) Compositions of cholinesterase inhibitors
SI2411354T1 (en) Stabilization of polyols
TWM372743U (en) Improved structure of Kendama
ZA201200531B (en) Pharmaceutical composition of rifampicin